Patent · US Active

B7-H1 fusion polypeptides for treating and preventing organ failure

US11679142B2 · kind B2 · utility

0Cited by

0References

14Claims

0Family size

Assignee

Fraunhofer-Gesellschaft zur förderung der angewandten Forschung e.V. · DE

Inventors

Andreas VON KNETHEN · Nidderau, DE
Michael Parnham · Bad Soden am Taunus, DE
Lisa Katharina Sha · Hattgenstein, DE

Key dates

Filing date	Mar 18, 2020
Grant date	Jun 20, 2023
Priority date	—
Expiry date	Jan 30, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention pertains to a fusion polypeptide for use in treating and/or preventing organ failure in a subject suffering from sepsis, said fusion polypeptide comprises at least (i) a first portion being a Fc portion of an immunoglobulin and (ii) a second portion comprising the extracellular portion of the human B7-H1 polypeptide or a variant thereof. Moreover, also encompassed by the invention is a polynucleotide encoding said fusion polypeptide for use in treating and/or preventing organ failure in a subject suffering from sepsis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.